Effect of Astragalus Membranaceus on the Improvement of Cognitive Function in Patients With Hypotension

• Status: Recruiting
• Trial end date: 2025-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The presence of hypotension in older adults increases their risk of cognitive decline. Astragalus membranaceus treatment can effectively improve the state of hypotension. In adults with both hypotension and cognitive impairment, the effectiveness of astragalus in improving their cognitive function has not been established. Therefore, this study aims to determine the efficacy and safety of Astragalus membranaceus treatment in improving cognitive function among patients with cognitive impairment with hypotension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fujian Medical University Union Hospital

Criteria

Inclusion Criteria:Participants with a clinical diagnosis of cognitive impairment and orthostatic hypotension. Adults signed informed consents.

-

Exclusion Criteria:Patients who have one of the following were excluded from this trial:

1. secondary hypotension.

2. definite hypersensitivity or contraindication to the study medications.

3. being treated or history of serious diseases such as stroke or transient ischemic attack, claustrophobia, bipolar disorder, schizophrenia, seizures, drug or alcohol abuse, malignancy, renal failure and dialysis treatment, liver disease (hepatitis), renal disease.

4. unable to have magnetic resonance imaging (MRI) or electroencephalogram (EEG).

5. use of health foods, supplements, and medicines that may affect cognitive function, 6) have severe visual and/or hearing impairment.

7) self-reported use of non-pharmacological or pharmacological therapies to treat hypotension.

8) during pregnancy or lactation 9) participation in other clinical studies within the past 3 months.

-